ProjectVICO-VTH02 – A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and…
Basic data
Acronym:
VICO-VTH02
Title:
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington disease
Duration:
20/04/2023 to 19/04/2027
Abstract / short description:
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington disease
Keywords:
Spinocerebellar Ataxia 1
Spinocerebellar Ataxia 3
Huntington disease
Involved staff
Managers
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Leiden, Netherlands